About 30 results found for searched term "G-1" (0.002 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1644 | AG-014699 phosphate | PARP |
| PF-01367338, Rucaparib phosphate | ||
| AG-014699 (PF-01367338, Rucaparib) is a PARP inhibitor with a Ki of 1.4 nM. | ||
| M1645 | AG14361 | PARP |
| AG14361 is a novel poly (ADP-ribose) polymerase-1 inhibitor with a GI50 of 10.9 µM. | ||
| M1658 | Axitinib | VEGFR/PDGFR |
| AG-013736 | ||
| Axitinib (AG013736) inhibits multiple targets including VEGFR, PDGFR and cKit. | ||
| M1686 | Bortezomib (PS-341) | Proteasome |
| Velcade; PS-341; LDP 341; MG 341; NSC 681239 | ||
| Bortezomib (PS-341) is a highly selective proteasome inhibitor with a ki value of 6nM. | ||
| M1713 | GDC-0449 (Vismodegib) | Smo |
| Vismodegib, HhAntag691 | ||
| GDC-0449 (Vismodegib) is a potent and specific hedgehog pathway inhibitor with IC50 values of 1.4 and 3.0μM for inhibition of ABCG2 and Pgp respectively. | ||
| M1715 | GDC-0941 (Pictilisib) | PI3K |
| Pictilisib | ||
| GDC-0941 is a selective and potent inhibitor of Class I PI3K, p110a IC50=0.003uM, U87MG IC50=0.95μM. | ||
| M1716 | Gemcitabine Hydrochloride | DNA/RNA Synthesis |
| Gemzar, LY-188011 | ||
| Gemcitabine (Gemzar, LY188011) inhibits DNA synthesis with an IC50 of 0.06 µM. | ||
| M1717 | GSK1904529A | IGF-1R |
| GSK1904529A selectively inhibits IGF-IR and IR with IC50s of 27 and 25 nmol/L, respectively. GSK1904529A shows poor activity (IC50>1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity. | ||
| M1719 | GSK461364 | PLK |
| GSK461364A | ||
| GSK461364 is a potent and selective small molecule inhibitor of Polo-like kinase 1 (PLK1) with a Ki of 2.2 nM. | ||
| M1721 | AZD4547 | FGFR |
| Fexagratinib; ABSK091 | ||
| AZD4547 is a potent, selective and orally active pan-FGFR inhibitor with IC50s of 0.2. 2.5, 1.8 and 165 nM for FGFR1, 2, 3 and 4, respectively. | ||
| M1733 | TG101348 | JAK |
| Fedratinib; SAR302503 | ||
| TG101348 is a selective small-molecule Janus kinase 2 (JAK2) inhibitor with IC50 of 3 nM. | ||
| M1758 | Foretinib | c-Met |
| GSK089; EXEL-2880; XL880; GSK1363089 | ||
| Foretinib (XL880, GSK1363089) is a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2 (VEGFR2) with IC50 value of 0.4 nM for c-MET. | ||
| M1759 | GSK1120212 (Trametinib) | MEK |
| JTP-74057, GSK212 | ||
| Trametinib (GSK1120212; Jtp-74057) is an orally effective MEK inhibitor with IC50 of 2 nM against MEK1 and MEK2, respectively. Trametinib can activate autophagy and induce apoptosis. | ||
| M1761 | Vemurafenib (PLX4032) | Raf |
| RG7204; RO5185426 | ||
| Vemurafenib (PLX4032) is a first-in-class, potent, selective inhibitor of B-Raf that inhibits RAFV600E and C-RAF-1 activity with IC50s of 31 nM and 48 nM, respectively.In addition, Vemurafenib induces autophagy. | ||
| M1772 | PKI-587 | PI3K |
| Gedatolisib; PF-05212384 | ||
| PKI-587 (Gedatolisib; PF-05212384) is a highly potent dual PI3K/mTOR kinase inhibitor with the IC50 value of 0.4nM. | ||
| M1779 | SGI-1776 | Pim |
| SGI-1776 is novel small molecule inhibitor of PIM kinase activity with IC50 of 7 ± 1.8, 363 ± 27.6 and 69 ± 9.2 nM for Pim-1, Pim-2, and Pim-3, respectively. | ||
| M1790 | MGCD0103 | HDAC |
| Mocetinostat | ||
| MGCD0103 is a novel HDAC inhibitor, highly specific for classes I and IV HDACs, with IC50 of 0.15, 0.29 and 1.66 μM for HDAC 1, HDAC 2 and HDAC 3 respectively. | ||
| M1795 | TGX-221 | PI3K |
| TGX-221 is a potent and specific cell permeable inhibitor of Phosphatidylinositol 3-kinase (PI3K) p110β(IC50 = 10nM). | ||
| M1799 | Imatinib Mesylate | Src-bcr-Abl |
| Gleevec, Glivec, CGP-57148B, STI-571 | ||
| Imatinib Mesylate is a Bcr-Abl tyrosine kinase inhibitor, with IC50 values of 2.9 and 3.9 μM for the inhibition of T-cell proliferation stimulated by PHA and DCs respectively. | ||
| M1802 | Lapatinib ditosylate monohydrate | EGFR/HER2 |
| GW572016 ditosylate monohydrate; GW2016 | ||
| Lapatinib (GW572016) ditosylate monohydrate is a selective and effective inhibitor of EGFR kinase (Ki = 3 nM), ErbB-2 kinase (Ki = 13 nM) and ErbB-4 kinase (Ki = 347 nM). | ||
| M1855 | Dabrafenib Mesylate | Raf |
| GSK-2118436B | ||
| Dabrafenib (GSK2118436) is a selective, orally bioavailable inhibitor of Mutant B-raf (BRAF) protein kinase with potential antineoplastic activity. | ||
| M1867 | PAC-1 | Caspase |
| Procaspase activating compound 1 | ||
| PAC-1 is a procaspase-activating compound; activates procaspase-3 to produce caspase-3 (EC50 = 0.22 μM). | ||
| M1886 | TG100-115 | PI3K |
| TG100-115 is a selective PI3K γ/δ inhibitor with IC50 values of 83 and 235 nM respectively. | ||
| M1887 | TG101209 | JAK |
| TG101209 is a novel small molecule, ATP-competitive JAK2-selective kinase inhibitor (IC50 = 6 nM). | ||
| M1902 | MG132 | Proteasome |
| Z-Leu-Leu-Leu-al; MG-132 | ||
| MG132 is a specific and potent cell-permeable proteasome inhibitor (IC50 = 100 nM, Ki = 4 nM). | ||
| M1909 | GW 791343 dihydrochloride | P2 Receptor |
| GW 791343 dihydrochloride is a non-competitive inhibitor of human P2X(7) receptor. | ||
| M1931 | GSK2126458 | PI3K |
| Omipalisib | ||
| GSK2126458 is a highly potent inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) with low picomolar to subnanomolar activity. | ||
| M1932 | GSK1838705A | ALK |
| GSK1838705A is a small-molecule kinase inhibitor that inhibits IGF-IR and the insulin receptor with IC50s of 2.0 and 1.6 nmol/L, respectively. | ||
| M1945 | CAL-101 (Idelalisib) | PI3K |
| Idelalisib; GS-1101 | ||
| CAL-101 (Idelalisib; GS-1101) is an oral PI3Kδ-specific inhibitor that has shown preclinical and clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. | ||
| M1978 | GSK1059615 | PI3K |
| GSK1059615 is a potent, ATP-competitive inhibitor of PI 3-kinase alpha (PI3Kα) with IC50 of 2 nM. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
